Topics

Symposium and Workshop Sessions are three hours each and Mini-Symposia are scheduled for 75 minutes each.

To ensure the safety of all attendees, we recommend that each individual select their seat for the entire duration of the session, including upon return from the break.

Symposia and Workshops are scheduled for Monday, November 14, 2022 from 9:00 AM–12:00 Noon and in the afternoon from 2:00 PM–5:00 PM; Tuesday, November 15, 2022 from 9:00 AM–12:00 Noon and in the afternoon from 2:00 PM–5:00 PM; and Wednesday, November 16, 2022 from 9:00 AM–12:00 Noon and in the afternoon from 2:00 PM–5:00 PM.

Symposia and Workshops

Scientific program is subject to change.

  • “3Rs” as a Conjoined Part of Drug Development: Understanding Challenges and Inventive 3R Opportunities for NHPs and Recovery Animals
  • Addressing the Global Challenge of Nitrosamine Impurities in Pharmaceutical Products
  • Applications for Duplex Sequencing of DNA in Genetic Toxicology: A Sneak Peek into the Future of Hazard Identification and Risk Assessment
  • Bioanalysis for Toxicologists
  • Chronic Toxicity Study Designs: Exploring Greater Flexibility for Appropriate Dosing Duration, Recovery Groups, and Species Selection to Support Human Safety Assessment While Balancing 3Rs Considerations
  • Consulting Practices: Everything You Need to Know about Consulting Agreements and Conflicts of Interest
  • Differing Approaches Used by Regulatory Agencies in Assessing Risk of Inhaled Substances
  • E14/S7B Q&A (R3) Guideline: A Roundtable Discussion on Perspectives and Practices
  • European Register of Toxicologists (ERT) Registration: What Is It? How Will It Help in My Career? What Is the Process to Apply for ERT Registration?
  • FDA Animal Rule for Toxicologists: Principles, Applications, and Future Direction
  • Hot Topics
  • ICH S1B(R1): New Approaches in the Carcinogenicity Assessment of Pharmaceuticals
  • Mutagenesis and Carcinogenesis Risk Evaluation for AAV and Lentiviral Gene Therapies
  • Rare Disease Programs for Small, Medium, and Large Patient Populations: One Size Doesn’t Fit All
  • Safety Assessment to Guide Drug Product Packaging Decisions
  • Special Considerations in Toxicology Study Design
  • When Are Repeat-Dose Toxicity Studies with Vaccines Informative?

A Special Thank You to Our Platinum and Gold Supporters

See all supporters here